Navigation Links
New cancer therapy may fight cardiovascular disease
Date:3/30/2010

AUGUSTA, Ga. - New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

Cancer and cardiovascular disease, both among top U.S. killers, share inflammation as a cause. Heat shock protein 90 inhibitors as a treatment could become additional common ground, said Dr. John Catravas, director of MCG's Vascular Biology Center.

"I think hsp90 inhibitors may be some of the best anti-inflammatory drugs we have," said Catravas, who is among the first scientists to explore the new cancer treatment's potential in cardiovascular disease.

Inflammation in the short term helps fight infection but becomes problematic when it is chronic or severe. For example, if acute inflammation causes contraction of endothelial cells (tight-fitting cells lining blood vessel walls), blood and fluid can leak into tissue a particularly deadly scenario in the lungs where it causes acute respiratory distress syndrome.

"Fifty percent of patients diagnosed with acute respiratory distress syndrome die because their endothelial cells have been so damaged." Catravas said. He and his colleagues have shown that hsp90 inhibitors can block this cell contraction and subsequent swelling in laboratory mice with acute inflammation.

A new $1.8 million, five-year grant from the National Heart, Lung and Blood Institute will enable the team to also study hsp90 inhibitors' impact on the cardiovascular complications that typically occur in people with the common double whammy of type 2 diabetes and obesity.

Complications arise when chronic inflammation causes proliferation of smooth muscle cells inside blood vessel walls, prompting previously smooth and flexible walls to thicken and stiffen. "Our hypothesis is that if we treat them with hsp90 inhibitors, we should be able to reduce the cardiovascular problems associated with type 2 diabetes," Catravas said.

Hsp90 activates other proteins and keeps them on task a multi-faceted role that leads the researchers to suspect that its inflammation-promoting role is multi-faceted as well. The functions are closely interwoven: enzymes critical to inflammation also activate hsp90.

Despite their critical role in the body, blocking hsp90 in disease states doesn't seem to cause undue problems. "Not all proteins associated with inflammation are bad, and when you block the good ones, you may have side effects," Catravas said. "But cancer indicates that the inhibitors have much higher affinity for active hsp90 and cancer has higher concentrations of active hsp90 than normal tissue." Catravas' team has shown that inflamed tissue has significantly more active hsp90 as well. "That is one of the beauties of the hsp90 inhibitors, he said.

They are focusing on three ways the inhibitors could block inflammation in cardiovascular disease. One is by blocking NFкB, which promotes synthesis of inflammation-promoting proteins. "We want to show if one of the ways it blocks especially chronic inflammation, which is NFкB-dependent, is by preventing NFкB activation," he said.

They'll inhibit NFкB then see if hsp90 inhibitors are still active and measure NFкB activity in mice treated with hsp90 inhibitors. They also want to delineate how inhibitors block NFкB, to see if they can find an even better way than hsp90 inhibitors to block inflammation. They'll also further test their hypothesis that inhibitors selectively target hsp90 in inflamed, rather than normal, tissue.

Anti-inflammatory agents already in wide use likely aren't good options for inflammation-related cardiovascular disease, Catravas said, noting unacceptable side effects particularly with long-term use. He hopes hsp90 inhibitors will provide a less toxic, multi-target approach for some patients, he said. "This is the beginning of the field."


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert

Related biology news :

1. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
2. Advances reported in quest for drugs targeting childhood cancer
3. Development of new anti-cancer gene therapy approach using lentiviral vectors
4. Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients
5. New way discovered to predict which breast cancer patients should be treated with anthracyclines
6. Vaccine could delay bowel inflammation and colon cancer, says Pitt research
7. IU researchers target vascular disease linked to cancer-causing gene mutation
8. High dietary phosphate intake may promote skin cancer formation
9. Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology
10. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
11. Could regulating intestinal inflammation prevent colon cancer?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology: